	US 11,945,864 B2
	Monoclonal antibody specifically binding to LAG-3 and use thereof
Sang Pil Lee, Daejeon (KR); Ji-Young Shin, Daejeon (KR); Sunha Yoon, Daejeon (KR); Yunseon Choi, Daejeon (KR); Jae Eun Park, Daejeon (KR); Ji Su Lee, Daejeon (KR); Youngja Song, Daejeon (KR); Gisun Baek, Daejeon (KR); Seok Ho Yoo, Daejeon (KR); Yeung-chul Kim, Daejeon (KR); Dong Jung Lee, Daejeon (KR); Bum-Chan Park, Daejeon (KR); and Young Woo Park, Daejeon (KR)
Assigned to Y-BIOLOGICS INC., Daejeon (KR)
Appl. No. 17/051,630
Filed by Y-BIOLOGICS INC., Daejeon (KR)
PCT Filed Jun. 28, 2019, PCT No. PCT/KR2019/007877 § 371(c)(1), (2) Date Oct. 29, 2020, PCT Pub. No. WO2020/005003, PCT Pub. Date Jan. 2, 2020.
Claims priority of application No. 10-2018-0075581 (KR), filed on Jun. 29, 2018.
Prior Publication US 2021/0238283 A1, Aug. 5, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); G01N 33/574 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 45/06 (2013.01); A61K 47/6849 (2017.08); G01N 33/574 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2319/03 (2013.01)]

16 Claims

1. A monoclonal antibody or an antigen-binding fragment thereof specifically binding to lymphocyte-activation gene 3 (LAG-3), comprising:

a heavy chain variable region comprising:

heavy chain CDR1 represented by SEQ ID NO: 1 or SEQ ID NO: 27;

heavy chain CDR2 represented by SEQ ID NO: 2; and

heavy chain CDR3 represented by SEQ ID NO: 3; and

a light chain variable region comprising:

light chain CDR1 represented by SEQ ID NO: 8, SEQ ID NO: 53 or SEQ ID NO: 57;

light chain CDR2 represented by Asp Ala Ser; and

light chain CDR3 represented by SEQ ID NO: 10, SEQ ID NO: 33 or SEQ ID NO: 60.